Peer-to-peer learning hub

Play Video

Improving ILD Diagnosis and Predicting Clinical Progression with the Envisia Genomic Classifier

Speakers discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in the diagnosis and prognosis of ILD. New data is presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic ILD.

Case Studies & Presentations

Envisia resource library

Watch case studies and testimonials from physicians or on-demand videos about Envisia and its clinical utility.

Video Thumbnail
Play button

Utility of Envisia Genomic Classifier in Multi Disciplinary ILD Management at ATS 2021

Panelists discuss the challenges in making an early accurate diagnosis in patients with diverse Interstitial Lung Diseases (ILD), review the latest published clinical validation and utility data for the Envisia Genomic Classifier, and discuss the role of the Envisia classifier in the diagnosis and prognosis of ILD patients.
Video Thumbnail
Play button

Envisia Physician Testimonial

Hear from Dr. Nina Maouelainin how she integrated Envisia Genomic Classifier into her clinical practice and the test’s impact on patient management.

Detects genomic UIP pattern to improve ILD diagnostic confidence

Usual interstitial pneumonia (UIP) is a critical factor in differentiating idiopathic pulmonary fibrosis (IPF) from other interstitial lung diseases (ILDs). The Envisia classifier improves ILD diagnostic and prognostic confidence, and can identify twice as many UIP patients than radiology alone when combined with HRCT.